• Moderna launched a private placement of USD 2 billion convertible senior notes due 2032.
• Initial purchasers hold an option to buy up to an additional USD 300 million of the notes within 13 days of issuance.
• Total potential issuance size stands at USD 2.3 billion.
• Notes are senior unsecured obligations with no regular interest or principal accretion.
• Proceeds earmarked for capped call costs, oncology investment flexibility, general corporate purposes, debt repayment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608270720ACCESSWRNAPR_____1213089) on August 27, 2026, and is solely responsible for the information contained therein.